Nephro-Urology Monthly

Published by: Kowsar

Relationship Between Plasma Adiponectin Level With Inflammatory and Metabolic Markers in Patients With Chronic Kidney Disease

Omid Sedighi 1 and Saeid Abediankenari 2 , *
Authors Information
1 Department of Nephrology, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, IR Iran
2 Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2014, 6 (1); e11743
  • Published Online: December 15, 2013
  • Article Type: Research Article
  • Received: April 23, 2013
  • Revised: May 12, 2013
  • Accepted: May 23, 2013
  • DOI: 10.5812/numonthly.11743

To Cite: Sedighi O, Abediankenari S. Relationship Between Plasma Adiponectin Level With Inflammatory and Metabolic Markers in Patients With Chronic Kidney Disease, Nephro-Urol Mon. 2014 ; 6(1):e11743. doi: 10.5812/numonthly.11743.

Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006; 98(12): 1603-8[DOI][PubMed]
  • 2. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118(5): 1645-56[DOI][PubMed]
  • 3. Chudek J, Adamczak M, Nieszporek T, Wiecek A. The adipose tissue as an endocrine organ-a nephrologists' perspective. Contrib Nephrol. 2006; 151: 70-90[DOI][PubMed]
  • 4. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000; 15(4): 454-7[PubMed]
  • 5. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, et al. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis. 2010; 20(1): 56-63[DOI][PubMed]
  • 6. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13(1): 134-41[PubMed]
  • 7. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 2004; 65(1): 274-81[DOI][PubMed]
  • 8. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003; 35(6): 2186-9[PubMed]
  • 9. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17(9): 2599-606[DOI][PubMed]
  • 10. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 2003; 52(10): 1274-8[PubMed]
  • 11. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16(4): 1091-8[DOI][PubMed]
  • 12. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol. 2005; 153(1): 91-8[DOI][PubMed]
  • 13. Shen Y, Peake PW, Kelly JJ. Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton). 2005; 10(6): 599-605[DOI][PubMed]
  • 14. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl. 2003; (84)-102[PubMed]
  • 15. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int. 2007; 71(12): 1279-86[DOI][PubMed]
  • 16. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008; 114(5): 361-74[DOI][PubMed]
  • 17. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007; 165(2): 164-74[DOI][PubMed]
  • 18. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, et al. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun. 2005; 335(4): 1254-63[DOI][PubMed]
  • 19. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J. 2008; 409(3): 623-33[DOI][PubMed]
  • 20. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008; 129(5): 815-22[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments